Antiphospholipid antibodies and prediction of pregnancy outcomes in treated APS women
| Outcome, models . | aPLAbs . | aOR (95%CI) . | P . |
|---|---|---|---|
| Abortion (embryonic loss) | |||
| LA | 0.98 (0.62-1.57) | .95 | |
| aCL-G | 1.08 (0.64-1.84) | .75 | |
| aβ2GP1-G | 0.72 (0.35-1.43) | .33 | |
| Triple positivity | 0.83 (0.49-1.39) | .48 | |
| Fetal loss | |||
| LA | 1.28 (0.73-2.24) | .38 | |
| aCL-G | 1.16 (0.74-1.82) | .53 | |
| aβ2GP1-G | 1.29 (0.76-2.18) | .34 | |
| Triple positivity | 1.13 (0.64-1.99) | .67 | |
| PE | |||
| LA | 1.67 (0.87-3.18) | .14 | |
| aCL-G | 0.81 (0.46-1.42) | .46 | |
| aβ2GP1-G | 1.14 (0.58-2.22) | .71 | |
| Triple positivity | 1.61 (0.90-2.87) | .14 | |
| Premature birth | |||
| LA | 0.87 (0.53-1.42) | .57 | |
| aCL-G | 1.41 (0.87-2.29) | .16 | |
| aβ2GP1-G | 1.24 (0.70-2.18) | .46 | |
| Triple positivity | 1.64 (0.92-2.93) | .13 | |
| SGA neonate | |||
| LA | 1.67 (0.97-2.89) | .07 | |
| aCL-G | 0.97 (0.58-1.63) | .92 | |
| aβ2GP1-G | 0.98 (0.54-1.84) | .97 | |
| Triple positivity | 1.49 (0.88-2.49) | .15 | |
| Any placenta-mediated complications | |||
| LA | 1.54 (0.91-2.61) | .11 | |
| aCL-G | 0.93 (0.58-1.48) | .75 | |
| aβ2GP1-G | 1.07 (0.61-1.87) | .82 | |
| Triple positivity | 1.57 (0.86-2.52) | .16 |
| Outcome, models . | aPLAbs . | aOR (95%CI) . | P . |
|---|---|---|---|
| Abortion (embryonic loss) | |||
| LA | 0.98 (0.62-1.57) | .95 | |
| aCL-G | 1.08 (0.64-1.84) | .75 | |
| aβ2GP1-G | 0.72 (0.35-1.43) | .33 | |
| Triple positivity | 0.83 (0.49-1.39) | .48 | |
| Fetal loss | |||
| LA | 1.28 (0.73-2.24) | .38 | |
| aCL-G | 1.16 (0.74-1.82) | .53 | |
| aβ2GP1-G | 1.29 (0.76-2.18) | .34 | |
| Triple positivity | 1.13 (0.64-1.99) | .67 | |
| PE | |||
| LA | 1.67 (0.87-3.18) | .14 | |
| aCL-G | 0.81 (0.46-1.42) | .46 | |
| aβ2GP1-G | 1.14 (0.58-2.22) | .71 | |
| Triple positivity | 1.61 (0.90-2.87) | .14 | |
| Premature birth | |||
| LA | 0.87 (0.53-1.42) | .57 | |
| aCL-G | 1.41 (0.87-2.29) | .16 | |
| aβ2GP1-G | 1.24 (0.70-2.18) | .46 | |
| Triple positivity | 1.64 (0.92-2.93) | .13 | |
| SGA neonate | |||
| LA | 1.67 (0.97-2.89) | .07 | |
| aCL-G | 0.97 (0.58-1.63) | .92 | |
| aβ2GP1-G | 0.98 (0.54-1.84) | .97 | |
| Triple positivity | 1.49 (0.88-2.49) | .15 | |
| Any placenta-mediated complications | |||
| LA | 1.54 (0.91-2.61) | .11 | |
| aCL-G | 0.93 (0.58-1.48) | .75 | |
| aβ2GP1-G | 1.07 (0.61-1.87) | .82 | |
| Triple positivity | 1.57 (0.86-2.52) | .16 |
All results are adjusted for predictors with P < .25 in the univariate analysis (adjusted odds ration [aOR]) (see Table 6).
aβ2GP1-G, positive for anti-β2-glycoprotein I IgG; aCL-G, positive for anticardiolipin IgG; aPLAbs, antiphospholipid antibodies; LA, positive for lupus anticoagulant; triple positivity, association of a positive LA test, a positive aCL-Ab test, and a positive aβ2GP1-Ab test.